News | Implantable Cardiac Monitor (ICM) | July 01, 2019

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in Europe

Next-generation ICM makes injection, monitoring and diagnosis of arrhythmias easy and efficient

Biotronik Launches Biomonitor III Injectable Cardiac Monitor in the CE Region

July 1, 2019 – Biotronik announced the European market release of its new injectable cardiac monitor (ICM), Biomonitor III, following CE mark approval. The novel device is designed to help patients with irregular heart rhythms by documenting suspected arrhythmia or unexplained syncope with increased clarity.

As the most common type of arrhythmia, 33.5 million patients worldwide suffer from atrial fibrillation (AF).1 It is associated with a five-fold increase in risk of stroke, a three-fold increase in incidence of congestive heart failure and higher mortality.2 Aiming to improve the accuracy of arrhythmia detection and diagnosis, Biotronik’s new ICM offers increased signal quality.3

“What I like about Biomonitor III is the ease of use and the high signal fidelity,” said Associate Prof. Paul Gould, cardiologist and electrophysiologist at St Andrew’s War Memorial Hospital, Brisbane, Australia. “This coupled with the automatic Home Monitoring provides an excellent resource to establish a rhythm symptom correlation or to detect occult arrhythmias in my patients." 

Biomonitor III’s BIOvector technology is designed to deliver high-definition signals. As a result, the high signal amplitudes and visibility of the p-waves3 make it easier for the physician to confidently evaluate arrhythmias. 

Biotronik’s next-generation ICM is 60 percent smaller than its predecessor, BioMonitor 2, and comes ready to inject, with the device pre-assembled in a one-piece injection tool. To optimize patient comfort, Biomonitor III offers a very small size and flexible sensing antenna. The device is injected under the skin with a very small incision, facilitating in-office treatments. 

The device works with Biotronik’s fully automated, ‘plug in and go’ Home Monitoring. Due to automatic pairing, initialization and data transmission, no active patient involvement is required. The new product also features Intelligent Memory Management, which prevents the overwriting of clinically relevant episodes. Thus, no relevant information is missed.

For more information: www.biotronik.com

 

References

1. Chugh S.S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation, 129 (2014):837-847.

2. Camm A.J. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.

3. BIO|CONCEPT.BIOMONITOR III Study. Data on file.

Related Content

Feature | Atrial Fibrillation

Improved short-term monitoring methods for patients with stroke risk can increase early detection of atrial fibrillation ...

Home December 07, 2021
Home
News | Atrial Fibrillation

November 17, 2021 — People with atrial fibrillation (AFib) who underwent individualized testing to discover triggers for ...

Home November 17, 2021
Home
News | Atrial Fibrillation

September 28, 2021 — Image-guided fibrosis ablation in addition to pulmonary vein isolation (PVI) does not improve ...

Home September 28, 2021
Home
News | Atrial Fibrillation

September 13, 2021 — Ablation plus cardiac resynchronization therapy (CRT) is superior to pharmacological rate control ...

Home September 13, 2021
Home
News | Atrial Fibrillation

September 8, 2021 — Continuous heart rhythm monitoring – with anticoagulation if atrial fibrillation is detected – does ...

Home September 08, 2021
Home
News | Atrial Fibrillation

August 9, 2021 — Adagio Medical Inc., a provider of catheter ablation technologies for atrial fibrillation (AF) and ...

Home August 09, 2021
Home
News | Atrial Fibrillation

June 23, 2021 — The U.S. Food and Drug Administration (FDA) expanded approval for Medtronic's Arctic Front Family of ...

Home June 23, 2021
Home
News | Atrial Fibrillation

April 19, 2021 — National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $462,689 to Rhythm ...

Home April 19, 2021
Home
News | Atrial Fibrillation

March 3, 2021 — Farapulse Inc. announced the first patients were treated in the ADVENT Trial, a U.S. Food and Drug ...

Home March 03, 2021
Home
News | Atrial Fibrillation

January 29, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Medtronic's DiamondTemp Ablation (DTA) system ...

Home January 29, 2021
Home
Subscribe Now